Abstract
An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have